Navigation Links
Trading Of Onyx Pharmaceuticals Common Stock Halted
Date:6/20/2012

SOUTH SAN FRANCISCO, Calif., June 20, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that NASDAQ has halted trading of the company's common stock.   The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) is meeting this afternoon to discuss the company's New Drug Application (NDA) for Kyprolis™ (proposed brand name for carfilzomib) under the accelerated approval pathway.

The NDA for Kyprolis for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies that included a proteasome inhibitor and an immunomodulatory agent is currently being reviewed by the U.S. FDA, and the anticipated date for completion of review under the PDUFA guidelines is July 27, 2012.

Conference Call Today
The Onyx management team will host a webcast and conference call to discuss the ODAC recommendation today at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time).

To access a live audio webcast of the conference call, log onto the company's website at: http://www.onyx.com/investors/event-calendar.

To access the live conference call, dial (847) 585-4405 and use the passcode 32594605. A replay of the call will be available on the Onyx website or by dialing (630) 652-3042 and using the passcode 3259 4605# approximately two hours after the conference call concludes through July 4, 2012.

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx.com.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. American Oriental Bioengineering Inc. Announces Suspension of Trading in its Common Stock and the Initiation of Delisting Proceedings by NYSE
2. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
3. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
4. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
5. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
6. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
7. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
8. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
9. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
10. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
11. Valeant Pharmaceuticals To Host Investor Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology:
(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to ... “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa wore his ... of Greater Boston, in a NALA North American Speaker Series (NASS) segment. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... their work assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution ... Solutions, a leading ERP expert that specializes in long-term care, Brooke Grove now ...
(Date:4/28/2017)... ... ... Christie Medical Holdings, Inc. , with its market-leading vein finder ... a leader in infusion therapy and pain management. , Intravenous (IV) therapy plays ... patients receiving a peripheral IV catheter as part of their treatment plan. Many hospitals ...
(Date:4/27/2017)... Minnesota (PRWEB) , ... April 27, 2017 , ... ... and her husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). ... Woodruff, retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. ...
Breaking Medicine News(10 mins):